{
    "clinical_study": {
        "@rank": "147816", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1 Non elderly receiving ASP1941", 
                "arm_group_type": "Experimental", 
                "description": "healthy subjects age 18 to 45 years receiving ASP1941"
            }, 
            {
                "arm_group_label": "Arm 2 Non elderly receiving placebo", 
                "arm_group_type": "Experimental", 
                "description": "healthy subjects age 18 to 45 years receiving placebo"
            }, 
            {
                "arm_group_label": "Arm 3 Elderly  receiving ASP1941", 
                "arm_group_type": "Experimental", 
                "description": "healthy subjects age \u2265 65 years receiving ASP1941"
            }, 
            {
                "arm_group_label": "Arm 4 Elderly receiving placebo", 
                "arm_group_type": "Experimental", 
                "description": "healthy subjects age \u2265 65 years receiving placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of the pharmacokinetic profile and safety and tolerability of ASP1941after\n      repeat dosing and the effect of ASP1941 on glucose levels in non elderly and elderly healthy\n      adult male and female subjects."
        }, 
        "brief_title": "Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults", 
        "completion_date": {
            "#text": "January 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Volunteers", 
            "Pharmacokinetics of ASP1941"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, healthy non-elderly (age 18-45 years, inclusive) or healthy elderly\n             (age 65 or over)\n\n          -  If female, subject is not pregnant or nursing, and uses medically acceptable\n             contraceptive method to prevent pregnancy from screening until study discharge\n\n          -  Body weigh between 60 and 100kg and body Mass Index between 20 and 30kg/m2, inclusive\n\n          -  Negative urine screen for drugs of abuse, including alcohol and cotinine\n\n        Exclusion Criteria:\n\n          -  History of type 1 or type 2 diabetes\n\n          -  Fasting plasma glucose level higher than 6.4mmol/L or hemoglobin A1c level higher\n             than 6.2%\n\n          -  Presence of renal glucosuria and/or proteinuria\n\n          -  Clinically significant history of asthma, eczema, and or any other allergic\n             condition.\n\n          -  Clinically significant history of upper gastrointestinal symptoms within the 4 weeks\n             prior to admission to the clinical unit.\n\n          -  History of any clinically significant neurological, gastrointestinal, renal, hepatic,\n             pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder\n             or disease, or any other medical condition that would preclude participation in the\n             study.\n\n          -  History of multiple drug allergies or a known allergy or suspected hypersensitivity\n             to the study drug or any chemically related derivatives of the study drug or any\n             components of the formulation\n\n          -  Has hepatitis or a positive result to serology test for hepatitis A antibody\n             Immunoglobulin M, hepatitis B surface antigen or hepatitis C virus at screening\n\n          -  Known to be positive for human immunodeficiency virus antibodies.\n\n          -  Donated one unit (450 mL) or more of blood or plasma within 60 days prior to the\n             first dose of study medication.\n\n          -  Has a history of consuming more than an average of 2 ounces of alcohol-containing\n             products per day or a history of alcoholism or drug/chemical abuse within the last 3\n             years.\n\n          -  Use of any tobacco or nicotine-containing products within 120 days prior to the first\n             dose of study medication.\n\n          -  Taken any prescribed systemic or topical medication within 21 days prior to the first\n             dose of study medication with the exception of contraceptives to prevent pregnancy.\n\n          -  Taken any systemic or topical over-the counter medication, complementary or\n             alternative medications, e.g., vitamins, herbal, or nutritional supplements, with the\n             exception of acetaminophen, within 10 days prior to the first dose of study\n             medication.\n\n          -  Taken an investigational drug within 30 days of the first dose of study medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678287", 
            "org_study_id": "1941-CL-0052"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1 Non elderly receiving ASP1941", 
                    "Arm 3 Elderly  receiving ASP1941"
                ], 
                "description": "oral", 
                "intervention_name": "ASP1941", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 2 Non elderly receiving placebo", 
                    "Arm 4 Elderly receiving placebo"
                ], 
                "description": "oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "ASP1941", 
        "lastchanged_date": "August 30, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miramar", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33025"
                }, 
                "name": "Comprehensive Phase One"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Dosing of ASP1941 and to Explore the Effect of ASP1941 on Glucose Levels in Healthy Adult Subjects (18 to 45 Years and \u2265 65 Years)", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Through Day 29"
            }, 
            {
                "measure": "Safety as assessed by vital signs, electrocardiogram (ECG), physical examination, and laboratory evaluations", 
                "safety_issue": "No", 
                "time_frame": "Through Day 29"
            }, 
            {
                "description": "Area under the curve over the time interval between consecutive dosing (AUCtau),Apparent total body clearance after extravascular dosing (CL/F), Maximum observed concentration (Cmax), Time to reach Cmax (Tmax), Terminal elimination half-life (t1/2), Apparent volume of distribution during the terminal phase after single or repeated extravascular dosing (Vz/F), Peak Trough Ratio (PTR)", 
                "measure": "Pharmacokinetic profile  of ASP1941 (plasma):AUCtau, CL/F, Cmax, tmax, t1/2, Vz/F, PTR", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 18 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose"
            }, 
            {
                "description": "Cumulative amount of drug excreted into urine up to the ending time of the last collection period (Ae), Fraction of the drug excreted in urine (Ae) in % up to the ending time of last collection period (Ae%), Cumulative amount of drug or glucose excreted into urine up to the collection time of the last measurable amount (Aelast),Fraction of drug excreted into urine (Ae) in % up to the collection time of the last measurable concentration (Aelast% ), Fraction of glucose excreted into urine up to 24 hrs (Ae24), Renal clearance (CLR)", 
                "measure": "Pharmacokinetic  profile  of  ASP1941 (urine): Ae, Ae%, Aelast, Aelast%, Ae24, CLR", 
                "safety_issue": "No", 
                "time_frame": "Day 1 at pre-dose and from 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48, 48 to 72, 72 to 96 hours post-dose"
            }, 
            {
                "description": "Cumulative amount of drug or glucose excreted into urine over the time interval between consecutive dosing (Aetau ), Fraction of drug or glucose excreted into urine (Aetau) in % over the time interval between consecutive dosing (Aetau%)", 
                "measure": "Pharmacokinetic profile  of ASP1941 (urine): Aetau, Aetau%, Aelast, CLR", 
                "safety_issue": "No", 
                "time_frame": "Day 18 at pre-dose and from 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48, 48 to 72, 72 to 96 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678287"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamic profile  of  blood glucose: Cmax and AUCtau", 
                "safety_issue": "No", 
                "time_frame": "Day -1 at -24, -23.75, -23.5, -23, -22.5, -22, -21, -20, -18, -16, -12, -8 and 0 (predose) hours prior to dose on Day 1 and on Day 18 predose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose"
            }, 
            {
                "measure": "Pharmacodynamic profile  of  urine glucose: Aelast and Aetau", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 18"
            }, 
            {
                "measure": "Rate of glucose excretion per sampling interval", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 18"
            }, 
            {
                "measure": "Rate of glucose excretion over 24 hours", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 18"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}